Latest News

Functional reconstructive urology emerged gradually as anatomical success proved insufficient—enabled by urodynamics, neurourology, and institutional milestones, according to Sasha Vereecken, BScN, RN.

An analysis of NHANES data found higher ultra-processed food intake was associated with increased prostate cancer risk among US men.

In this episode of Pearls & Perspectives, Amy Pearlman, MD, and plastic surgeon Andrew T. Cohen, MD, FACS, discuss managing patient expectations and the importance of cultivating balance outside of surgical practice.

Narmina Khanmammadova, MD, discusses interim findings on preoperative pelvic floor therapy and its potential to improve continence recovery after HoLEP.

Jessica Yih, MD, reviews evidence on testosterone therapy for female sexual dysfunction, highlighting promising but limited data in premenopausal women.

A claims-based analysis found blue light cystoscopy was associated with increase health care resource utilization in NMIBC without significantly increasing total costs.

A real-world analysis found that achieving a PSA level below 0.2 ng/mL was associated with improved overall survival in mCSPC.

These FAQs highlight key recommendations and practical takeaways from the 2026 AUA/ASTRO Clinically Localized Prostate Cancer guideline amendment.

The phase 3 PSMAddition trial found that adding lutetium Lu 177 vipivotide tetraxetan to ADT and an ARPI significantly improved rPFS in mHSPC.

In this episode of The UroOnc Minute, Mark D. Tyson, II, MD, MPH, discusses the importance of BCG maintenance therapy in NMIBC and shares strategies for navigating treatment barriers and toxicity.

Keith Xavier, MD, discusses the role of Altaviva in treating men with overactive bladder and urge urinary incontinence, including patient selection, clinical considerations, and its place among third-line therapies.

Abraham Morgentaler, MD, joins Neil Baum, MD, to discuss the historical origins of the belief that testosterone drives prostate cancer and the new framework presented in his recent Journal of Urology publication.

The registrational trial will compare ivonescimab plus enfortumab vedotin vs pembrolizumab plus enfortumab vedotin for locally advanced or metastatic urothelial carcinoma.